Genomic Alterations and MYD88


Journal

Targeted oncology
ISSN: 1776-260X
Titre abrégé: Target Oncol
Pays: France
ID NLM: 101270595

Informations de publication

Date de publication:
04 2020
Historique:
pubmed: 3 4 2020
medline: 15 12 2020
entrez: 3 4 2020
Statut: ppublish

Résumé

Diffuse large B-cell lymphoma (DLBCL) is a clinically heterogeneous malignancy. Following front-line immunochemotherapy, 30-40% of DLBCL patients develop relapsed or refractory (r/r) disease, which can be treated with ibrutinib. It has been previously reported that MYD88 Here, we aimed to gather understanding of MYD88 In this study, tissue samples from DLBCL patients (n = 212) were retrospectively collected and sequenced by target-capturing panels of either 413 or 112 genes that are frequently mutated in non-Hodgkin's lymphoma. Sixty patients with MYD88 mutations and available clinical information were included for further analysis. Seven MYD88 This study adds clinical observations with MYD88

Sections du résumé

BACKGROUND
Diffuse large B-cell lymphoma (DLBCL) is a clinically heterogeneous malignancy. Following front-line immunochemotherapy, 30-40% of DLBCL patients develop relapsed or refractory (r/r) disease, which can be treated with ibrutinib. It has been previously reported that MYD88
OBJECTIVE
Here, we aimed to gather understanding of MYD88
PATIENTS AND METHODS
In this study, tissue samples from DLBCL patients (n = 212) were retrospectively collected and sequenced by target-capturing panels of either 413 or 112 genes that are frequently mutated in non-Hodgkin's lymphoma. Sixty patients with MYD88 mutations and available clinical information were included for further analysis.
RESULTS
Seven MYD88
CONCLUSIONS
This study adds clinical observations with MYD88

Identifiants

pubmed: 32239385
doi: 10.1007/s11523-020-00710-4
pii: 10.1007/s11523-020-00710-4
doi:

Substances chimiques

MYD88 protein, human 0
Myeloid Differentiation Factor 88 0
Piperidines 0
Pyrazoles 0
Pyrimidines 0
ibrutinib 1X70OSD4VX
Adenine JAC85A2161

Types de publication

Case Reports Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

221-230

Subventions

Organisme : National Key Technology Support Program
ID : 2014BAI09B12
Pays : International
Organisme : National New Drug Innovation Program
ID : 2017ZX09304015
Pays : International
Organisme : CAMS Innovation Fund for Medical Sciences (CIFMS)
ID : 2016-I2M-1-001
Pays : International

Références

J Biol Chem. 1998 May 15;273(20):12203-9
pubmed: 9575168
J Biol Chem. 2003 Oct 17;278(42):41443-51
pubmed: 12888566
Blood. 2005 Nov 1;106(9):3183-90
pubmed: 16046532
Nature. 2000 Feb 3;403(6769):503-11
pubmed: 10676951
J Clin Oncol. 2014 Sep 20;32(27):3059-68
pubmed: 25113753
Blood. 2013 Aug 15;122(7):1256-65
pubmed: 23699601
Blood. 2010 Sep 23;116(12):2040-5
pubmed: 20548096
Cancer Control. 2012 Jul;19(3):204-13
pubmed: 22710896
Nat Med. 2015 Aug;21(8):922-6
pubmed: 26193343
Nat Genet. 2011 Jul 31;43(9):830-7
pubmed: 21804550
Lancet Haematol. 2019 Feb;6(2):e67-e78
pubmed: 30642819
Genes Chromosomes Cancer. 2014 Feb;53(2):144-53
pubmed: 24327543
Blood. 2017 Oct 5;130(14):1676-1679
pubmed: 28794071
J Clin Oncol. 2019 May 20;37(15):1285-1295
pubmed: 30901302
Expert Rev Hematol. 2016 Mar;9(3):255-69
pubmed: 26652775
Nat Med. 2018 May;24(5):679-690
pubmed: 29713087
Blood. 2017 Oct 19;130(16):1800-1808
pubmed: 28774879
Clin Cancer Res. 2016 Jun 1;22(11):2755-64
pubmed: 26792260
Nature. 2011 Jul 27;476(7360):298-303
pubmed: 21796119
Sci Rep. 2017 May 11;7(1):1785
pubmed: 28496180
J Mol Diagn. 2018 Mar;20(2):264-266
pubmed: 29482770
Nat Biotechnol. 2013 Mar;31(3):213-9
pubmed: 23396013
Oncol Lett. 2018 Feb;15(2):1707-1715
pubmed: 29403563
N Engl J Med. 2018 Apr 12;378(15):1396-1407
pubmed: 29641966
Genome Res. 2010 Sep;20(9):1297-303
pubmed: 20644199
Diagn Pathol. 2011 Aug 22;6:77
pubmed: 21854649
Pathologica. 2010 Jun;102(3):83-7
pubmed: 21171509
J Clin Oncol. 1999 Apr;17(4):1244
pubmed: 10561185
J Mol Diagn. 2017 Jul;19(4):525-536
pubmed: 28502728
Nature. 2011 Feb 3;470(7332):115-9
pubmed: 21179087
Leukemia. 2014 Oct;28(10):2104-6
pubmed: 24903481
Clin Cancer Res. 2017 May 1;23(9):2232-2244
pubmed: 27923841
Science. 1997 Nov 28;278(5343):1612-5
pubmed: 9374458
Blood Cancer J. 2013 Sep 06;3:e139
pubmed: 24013661
Bioinformatics. 2012 May 15;28(10):1307-13
pubmed: 22474122
Blood. 2016 Feb 18;127(7):869-81
pubmed: 26702065
Proc Natl Acad Sci U S A. 2013 Jan 22;110(4):1398-403
pubmed: 23292937

Auteurs

Shiyu Jiang (S)

Department of Medical Oncology, Beijing Key Laboratory of Clinical Study On Anticancer Molecular Targeted Drugs, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, No. 17 Panjiayuan Nanli, Chaoyang District, Beijing, 100021, China.

Yan Qin (Y)

Department of Medical Oncology, Beijing Key Laboratory of Clinical Study On Anticancer Molecular Targeted Drugs, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, No. 17 Panjiayuan Nanli, Chaoyang District, Beijing, 100021, China.

Lin Gui (L)

Department of Medical Oncology, Beijing Key Laboratory of Clinical Study On Anticancer Molecular Targeted Drugs, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, No. 17 Panjiayuan Nanli, Chaoyang District, Beijing, 100021, China.

Peng Liu (P)

Department of Medical Oncology, Beijing Key Laboratory of Clinical Study On Anticancer Molecular Targeted Drugs, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, No. 17 Panjiayuan Nanli, Chaoyang District, Beijing, 100021, China.

Hongxin Jiang (H)

Department of Medical Oncology, Suzhou Municipal Hospital, Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou, 215001, Jiangsu Province, China.

Biao Liu (B)

Department of Pathology, Suzhou Municipal Hospital, Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou, 215001, Jiangsu Province, China.

Jianliang Yang (J)

Department of Medical Oncology, Beijing Key Laboratory of Clinical Study On Anticancer Molecular Targeted Drugs, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, No. 17 Panjiayuan Nanli, Chaoyang District, Beijing, 100021, China.

Sheng Yang (S)

Department of Medical Oncology, Beijing Key Laboratory of Clinical Study On Anticancer Molecular Targeted Drugs, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, No. 17 Panjiayuan Nanli, Chaoyang District, Beijing, 100021, China.

Xiaohui He (X)

Department of Medical Oncology, Beijing Key Laboratory of Clinical Study On Anticancer Molecular Targeted Drugs, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, No. 17 Panjiayuan Nanli, Chaoyang District, Beijing, 100021, China.

Shengyu Zhou (S)

Department of Medical Oncology, Beijing Key Laboratory of Clinical Study On Anticancer Molecular Targeted Drugs, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, No. 17 Panjiayuan Nanli, Chaoyang District, Beijing, 100021, China.

Xinhua Du (X)

Geneplus-Beijing, Beijing, 102206, China.

Yuting Yi (Y)

Geneplus-Beijing, Beijing, 102206, China.

Jing Lin (J)

Burning Rock Biotech, Guangzhou, Guangdong, China.

Yuankai Shi (Y)

Department of Medical Oncology, Beijing Key Laboratory of Clinical Study On Anticancer Molecular Targeted Drugs, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, No. 17 Panjiayuan Nanli, Chaoyang District, Beijing, 100021, China. syuankai@cicams.ac.cn.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH